275 related articles for article (PubMed ID: 31045462)
21. Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Kreitman RJ; Pastan I
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32756468
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeys.
Wang B; Liang M; Yao Z; Vainshtein I; Lee R; Schneider A; Zusmanovich M; Jin F; O'Connor K; Donato-Weinstein B; Iciek L; Lavallee T; Roskos L
J Pharm Sci; 2013 Jan; 102(1):250-61. PubMed ID: 23090886
[TBL] [Abstract][Full Text] [Related]
23. Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Shah NN; Bhojwani D; August K; Baruchel A; Bertrand Y; Boklan J; Dalla-Pozza L; Dennis R; Hijiya N; Locatelli F; Martin PL; Mechinaud F; Moppett J; Rheingold SR; Schmitt C; Trippett TM; Liang M; Balic K; Li X; Vainshtein I; Yao NS; Pastan I; Wayne AS
Pediatr Blood Cancer; 2020 May; 67(5):e28112. PubMed ID: 31944549
[TBL] [Abstract][Full Text] [Related]
24. Moxetumomab pasudotox as re-treatment for heavily-pretreated relapsed hairy cell leukemia.
Yurkiewicz IR; Coutre S; Ghesquieres H; Pastan I; Kreitman RJ
Leuk Lymphoma; 2021 Nov; 62(11):2812-2814. PubMed ID: 34030585
[No Abstract] [Full Text] [Related]
25. Immunoconjugates and new molecular targets in hairy cell leukemia.
Kreitman RJ
Hematology Am Soc Hematol Educ Program; 2012; 2012():660-6. PubMed ID: 23233649
[TBL] [Abstract][Full Text] [Related]
26. Management of Relapsed Hairy Cell Leukemia: A Systematic Review of Novel Agents and Targeted Therapies.
Siddiqui R; Sardar M; Shahzad M; Jose J; Selene I; Shah Z; Qureshi A; Shafqat M; Kashif R; Ahmad M; Mejia-Garcia A; Anwer F
Clin Lymphoma Myeloma Leuk; 2021 Oct; 21(10):659-666. PubMed ID: 34275772
[TBL] [Abstract][Full Text] [Related]
27. Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Kreitman RJ; Arons E; Stetler-Stevenson M; Fitzgerald DJ; Wilson WH; Pastan I
Leuk Lymphoma; 2011 Jun; 52 Suppl 2(Suppl 2):82-6. PubMed ID: 21599609
[TBL] [Abstract][Full Text] [Related]
28. The pharmacological management of hairy cell leukemia.
Ramos Perez J; Ravandi-Kashani F
Expert Opin Pharmacother; 2020 Aug; 21(11):1337-1344. PubMed ID: 32378970
[TBL] [Abstract][Full Text] [Related]
29. Management of hairy cell leukemia variant.
Robak T
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():53-6. PubMed ID: 21599606
[TBL] [Abstract][Full Text] [Related]
30. Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances.
Paillassa J; Maitre E; Troussard X
Curr Oncol Rep; 2022 Sep; 24(9):1133-1143. PubMed ID: 35403971
[TBL] [Abstract][Full Text] [Related]
31. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox.
Müller F; Cunningham T; Stookey S; Tai CH; Burkett S; Jailwala P; Stetler Stevenson M; Cam MC; Wayne AS; Pastan I
Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1867-E1875. PubMed ID: 29432154
[TBL] [Abstract][Full Text] [Related]
32. A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Short NJ; Kantarjian H; Jabbour E; Cortes JE; Thomas DA; Rytting ME; Daver N; Alvarado Y; Konopleva M; Kebriaei P; Wierda WG; DiNardo CD; Bivins C; McCue D; Richie MA; Ravandi F
Br J Haematol; 2018 Aug; 182(3):442-444. PubMed ID: 28616864
[No Abstract] [Full Text] [Related]
33. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
34. Hairy cell leukemia-new genes, new targets.
Kreitman RJ
Curr Hematol Malig Rep; 2013 Sep; 8(3):184-95. PubMed ID: 23892906
[TBL] [Abstract][Full Text] [Related]
35. Novel therapeutics in hairy cell leukemia.
Sarvaria A; Saven A
Expert Rev Hematol; 2019 Nov; 12(11):983-987. PubMed ID: 31380711
[No Abstract] [Full Text] [Related]
36. Novel therapeutic options for relapsed hairy cell leukemia.
Jain P; Polliack A; Ravandi F
Leuk Lymphoma; 2015; 56(8):2264-72. PubMed ID: 25563425
[TBL] [Abstract][Full Text] [Related]
37. Population pharmacokinetics, efficacy, and safety of moxetumomab pasudotox in patients with relapsed or refractory hairy cell leukaemia.
Kuruvilla D; Chia YL; Balic K; Yao NS; Kreitman RJ; Pastan I; Li X; Standifer N; Liang M; Tseng CM; Faggioni R; Roskos L
Br J Clin Pharmacol; 2020 Jul; 86(7):1367-1376. PubMed ID: 32077130
[TBL] [Abstract][Full Text] [Related]
38. A novel approach to assess domain specificity of anti-drug antibodies to moxetumomab pasudotox, an immunotoxin with two functional domains.
Vainshtein I; Sun B; Roskos LK; Liang M
J Immunol Methods; 2020 Feb; 477():112688. PubMed ID: 31676342
[TBL] [Abstract][Full Text] [Related]
39. Domain II of
Müller F; Cunningham T; Beers R; Bera TK; Wayne AS; Pastan I
Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29883379
[TBL] [Abstract][Full Text] [Related]
40. Treatment of hairy cell leukemia.
Chihara D; Kreitman RJ
Expert Rev Hematol; 2020 Oct; 13(10):1107-1117. PubMed ID: 32893700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
